PHST001
Advanced Solid Tumors
Phase 1Active
Key Facts
About Pheast Therapeutics
Pheast Therapeutics is a private, preclinical-stage biotech founded in 2020, focused on discovering and developing innate immune checkpoint inhibitors. Its core technology platform identifies novel 'don't eat me' signals, like CD24, to unleash macrophages against cancers resistant to existing immunotherapies. The company has initiated a Phase 1 trial for its lead anti-CD24 antibody, PHST001, and is backed by a $76M Series A round. Pheast aims to create next-generation therapies for patients with hard-to-treat solid tumors.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |